has accepted for review the New Drug Application (NDA) for its novel Bumetanide Nasal Spray (RSQ-777). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September ...

(www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid overload, today announced that the U.S. Food and Drug Administration (FDA) has ...

Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

The center is one of three that the UK-based company uses for research and development for its brands that include Sensodyne toothpaste, Centrum multivitamins, Flonase nasal spray, Advil pain relief ...